Differentiation in the Innovative Drug Sector Accelerates Further,China Universal CNI BIOMEDICINE ETF(159839) Rises 1.43% Intraday

NewTimeSpace News: As of 13:59 on March 31, 2026, the CSI Biomedical Index (399441) surged 1.36%. Its constituent stocks posted robust gains, with Asymchem Laboratories up 10.00%, Joinn Laboratories rising 6.17%, Pharmaron Beijing climbing 5.16%, and Gan & Lee Pharmaceuticals, Tigermed Group and other individual stocks following the upward trend. China Universal CNI BIOMEDICINE ETF(159839) advanced 1.43%, on track for a three consecutive winning streak, with the latest price at RMB 0.35. Over a longer timeframe, as of March 30, 2026, the ETF had recorded a cumulative increase of 7.72% in the past week. (The stocks listed above are merely constituent stocks of the index and do not constitute any specific investment recommendation.)

In terms of liquidity, China Universal CNI BIOMEDICINE ETFsaw an intraday turnover rate of 4.35% with a trading volume of RMB 39.1660 million. As of March 30, the ETF had an average daily trading volume of RMB 28.9513 million in the past week.

In terms of capital flows, the ETF recorded a latest net capital outflow of RMB 11.4703 million. Over the past 21 trading days, it saw net capital inflows on 13 days with a total inflow of RMB 75.0769 million, equivalent to a daily average net inflow of RMB 3.5751 million. (Data source: Wind)

Data showed that margin funds have been continuously building positions in the ETF. The latest margin purchase amount of China Universal CNI BIOMEDICINE ETFreached RMB 2.1778 million, with the latest margin balance standing at RMB 31.3531 million. (Data source: Wind)

As of March 30, the ETF’s net asset value (NAV) has risen 1.04% in the past year. In terms of profitability, as of March 30, 2026, since its inception, the ETF has registered a maximum monthly return of 27.69%, a longest consecutive monthly gain streak of 5 months with a cumulative increase of 31.17% during the streak, and an average monthly return of 5.93% in positive months. As of March 30, 2026, the ETF has achieved an annualized excess return over the benchmark of 2.26% in the past six months.

In terms of drawdown, as of March 30, 2026, China Universal CNI BIOMEDICINE ETFhas seen a relative drawdown of 0.11% compared to the benchmark year-to-date.

In terms of fees, the ETF charges a management fee rate of 0.50% and a custodian fee rate of 0.10%, with the lowest fee rates among comparable funds.

In terms of tracking accuracy, as of March 30, 2026, China Universal CNI BIOMEDICINE ETFhad a tracking error of 0.016% in the past three months, boasting a relatively high tracking accuracy among comparable funds.

From a valuation perspective, the CSI Biomedical Index tracked by the ETF has a latest trailing twelve months price-to-earnings ratio (PE-TTM) of only 37.54 times, at the 18.43rd percentile over the past year. This means the index’s valuation is lower than that in more than 81.57% of the time over the past year, standing at a historical low.

China Universal CNI BIOMEDICINE ETFclosely tracks the CSI Biomedical Index. The index takes listed companies engaged in the biomedical industry on the Shanghai, Shenzhen and Beijing Stock Exchanges as its sample universe, selects the top 30 securities as its constituent stocks based on a comprehensive ranking of market capitalization and liquidity, reflecting the overall operation of the biomedical industry and providing the market with an index investment target for the sub-sector.

Data showed that as of February 27, 2026, the top 10 weight stocks of the CSI Biomedical Index (399441) were WuXi AppTec, Fosun Pharma, Tigermed Group, Shanghai RAAS Blood Products, Changchun High-tech Industries, Pharmaron Beijing, Gan & Lee Pharmaceuticals, Bio-Thera Solutions, Asymchem Laboratories and Walvax Biotechnology respectively, with the combined weight of the top 10 stocks accounting for 55.33%. (The stocks listed above are merely constituent stocks of the index and do not constitute any specific investment recommendation.)

Century Securities stated that domestic innovative drugs have risen abruptly. The first profit of leading Biotech companies has kicked off a positive flywheel where revenue feeds back into R&D to deepen the moat, and the prosperity and differentiation of the innovative drug industry will accelerate further.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.